Last ten years were a remarkable and successful period of research and development of drugs to cure malaria
Dr Chris Hentschel has informed the MMV Board of his intention to step down as President and CEO in 2010. Chris has successfully led MMV since its inception in 1999 and feels it is now time for him to hand over to new leadership for the next decade.
Earlier this month, Chris presided over an event to celebrate MMV’s 10th Anniversary as a leading PDP committed to the discovery, development and delivery of new medicines combating malaria. The anniversary seminar was made memorable with a keynote speech from Dr Margaret Chan, Director General of the World Health Organization, and by the announcement from the Bill and Melinda Gates Foundation of a five year grant in continued support of MMV’s research activities.
The ten years under Chris’s leadership have been a remarkable and successful period of research and development of drugs to cure malaria. They include the registration with Novartis last year of Coartem® Dispersible, the first ever antimalarial registered to international standards, designed specifically for children. In addition, two new medicines are scheduled to be approved over the next two years.
The Board thanks Chris wholeheartedly for his major and invaluable contributions over all this time, and wishes him great success in his future endeavours.
The Board has initiated a global search for Chris’ successor and expects to make a further announcement in the first quarter of 2010.